The Global Healthy Living Foundation (GHLF), parent non-profit of the CreakyJoints® online patient community, today announced ...

Disease-associated vision changes are common in GCA, with no significant difference in visual improvement observed with IV glucocorticoids vs oral therapy.

Recent advances in the study of inflammatory vasculitides have underscored the complexity of both giant cell arteritis (GCA) and Takayasu arteritis (TAK). Research has increasingly revealed the ...

Ultrasound can be used as a first-line tool for regular and follow-up screening for aortic aneurysms in patients with giant cell arteritis due to a strong correlation with CT results, a study shows.

Patients with giant cell arteritis started tocilizumab therapy an average of 43 days after diagnosis, partly because of delays in insurance approval. Overall, 82 patients (average age, 73 years; 60% ...

A common medication already used for autoimmune diseases such as rheumatoid arthritis is effective for patients with giant cell arteritis, according to findings from a team at the Perelman School of ...

Please provide your email address to receive an email when new articles are posted on . Although it is known that the selective Janus kinase (JAK) inhibitor upadacitinib (Rinvoq, AbbVie) blocks the ...

ORLANDO -- Adding another twist to the ongoing debate about the effects of weight-loss drugs on vision, a retrospective ...

ABBV leans on booming Skyrizi and Rinvoq-driven sales to sustain growth and counter Humira's decline as Q3 results approach.

Topline data were announced from a phase 3 trial evaluating secukinumab in patients with polymyalgia rheumatica (PMR).

The US Food and Drug Administration (FDA) has approved AbbVie’s supplemental new drug application, updating the indication ...